Figure 6.
Immunohistochemistry (IHC) analysis of lung tumor section for EphA2 and proliferation marker-PCNA. YDPL and YDPL + telmisartan treated groups showed marked reduction in expression of both markers.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.